GeoVax Reports Q2 Financials and Prepares to Initiate GEO-MVA Pivotal Study
GeoVax Labs reported second-quarter financial results and advanced operations to prepare for the planned fourth-quarter initiation of a pivotal GEO-MVA immunobridging study under an expedited regulatory pathway, while continuing to develop its Gedeptin immuno-oncology platform.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day